Ida Rahmqvist
A5011246736- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Cancer, Hypoxia, and Metabolism
- Microplastics and Plastic Pollution
- Cancer Genomics and Diagnostics
- Toxic Organic Pollutants Impact
- Environmental Toxicology and Ecotoxicology
University of Gothenburg
2020-2024
The textile industry, while of major importance in the world economy, is a toxic industry utilizing and emitting thousands chemical substances into aquatic environment. aim this project was to study potentially harmful effects associated with leaching residues from three different types textiles: sportswear, children’s bath towels, denim using fish models (cell lines, larvae juvenile fish). A combination vitro vivo test systems used. Numerous biomarkers, ranging gene expression, cytotoxicity...
<p>Supplementary figures 1-4, supplementary tables and case information</p>
<p>Genomic profiles of tumor DNA generated by SNP microarray</p>
<p>Sanger sequencing of tumor and germline DNA</p>
<p>Levels of oncogenic ALK mutations in tissue samples</p>
<p>SNP array results</p>
<p>Sequencing results, ALK hotspot mutation sites</p>
<p>Sequencing results, all data</p>
<p>Coverage with the NB-ALK sequencing panel</p>
Abstract Patients with anaplastic lymphoma kinase (ALK)–driven neuroblastoma may respond to tyrosine inhibitors, but resistance treatment occurs and methods currently used for detection of residual disease have limited sensitivity. Here, we present a national unselected cohort five patients relapsed or refractory ALK-driven treated lorlatinib as monotherapy test the potential targeted circulating tumor DNA (ctDNA) analysis guide decisions in these patients. We developed sequencing panel...
<p>Supplementary figures 1-4, supplementary tables and case information</p>
<div>Abstract<p>Patients with anaplastic lymphoma kinase (ALK)–driven neuroblastoma may respond to tyrosine inhibitors, but resistance treatment occurs and methods currently used for detection of residual disease have limited sensitivity. Here, we present a national unselected cohort five patients relapsed or refractory ALK-driven treated lorlatinib as monotherapy test the potential targeted circulating tumor DNA (ctDNA) analysis guide decisions in these patients. We developed...
<p>Early detection of relapse and emergence an <i>HRAS</i> p.Q61L mutation during lorlatinib treatment in a patient (patient 5) with <i>ALK</i> p.F1174L-positive neuroblastoma. <b>A,</b> MIBG scans at initial diagnosis, the first relapse, after 4 months (partial response), second 10.5 treatment. <b>B,</b> Allele frequency tumor tissue different time points. <b>C,</b> Levels ctDNA. <b>D,</b> Clinical markers, values...
<p>Long-term response to lorlatinib in a patient (patient 4) with refractory <i>ALK</i> p.R1275Q-positive neuroblastoma. <b>A,</b> MIBG or <sup>68</sup>Ga-DOTATATE scans at the time of diagnosis, after induction chemotherapy, and 5 months treatment. Red arrows denote tumors. <b>B,</b> Levels ctDNA. <b>C,</b> Plasma methoxy noradrenaline. ND, not detected; URL, upper reference limit (0.7 nmol/L).</p>
<p>Baseline information</p>
<p>Sequencing results, all data</p>
<p>Genomic profiles of tumor DNA generated by SNP microarray</p>
<p>Detection of relapse with ctDNA analysis 9 months prior to clinical presentation in a patient (patient 2) <i>ALK</i> p.R1275Q-positive neuroblastoma treated lorlatinib. <b>A,</b> MIBG scans. <b>B,</b> Levels ctDNA. <b>C,</b> NSE. CS, Curie score; ND, not detected; TID, temozolomide, irinotecan and dinutuximab; URL, upper reference limit (16.3 µg/L).</p>
<p>Clinical response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma. Black arrows denote ongoing treatment follow-up. *Germline <i>ALK</i> variant. CR, complete response; PR partial response.</p>
<p>Levels of oncogenic ALK mutations in tissue samples</p>
<p>SNP array results</p>
<p>Lorlatinib treatment information</p>
<p>ctDNA analysis using the NB-ALK sequencing panel. Pink areas denote parts of <i>ALK</i> gene included in Recurrent mutations previously detected neuroblastoma or associated with resistance to TKIs that are covered by panel shown; hotspot bold. Angled numbers range amino acid positions each seven assays.</p>
<p>Sanger sequencing of tumor and germline DNA</p>
<p>Sequencing results, ALK hotspot mutation sites</p>